Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database.
Casarotto E, Chandwani S, Mortier L, Dereure O, Dutriaux C, Dalac S, Scherrer E, Lévy-Bachelot L, Verdoni L, Farge G, Allayous C, Oriano B, Dalle S, Lebbé C. Casarotto E, et al. Among authors: dalac s. Immunotherapy. 2021 Aug;13(11):905-916. doi: 10.2217/imt-2021-0077. Epub 2021 Jun 2. Immunotherapy. 2021. PMID: 34074114 Free article.
Cutaneous malignant melanoma and neurofibromatosis type 1.
Guillot B, Dalac S, Delaunay M, Baccard M, Chevrant-Breton J, Dereure O, Machet L, Sassolas B, Zeller J, Bernard P, Bedane C, Wolkenstein P; French Group of Cutaneous Oncology. Guillot B, et al. Among authors: dalac s. Melanoma Res. 2004 Apr;14(2):159-63. doi: 10.1097/00008390-200404000-00014. Melanoma Res. 2004. PMID: 15057048
Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France.
Grange F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hédelin G, Dalac S, Truchetet F, Michel C, Batard ML, Baury B, Halna JM, Schmutz JL, Delvincourt C, Reuter G, Dalle S, Bernard P, Danzon A. Grange F, et al. Among authors: dalac s. Arch Dermatol. 2008 May;144(5):629-36. doi: 10.1001/archderm.144.5.629. Arch Dermatol. 2008. PMID: 18490589
The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in France.
Durbec F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hédelin G, Dalac S, Truchetet F, Michel C, Batard ML, Domissy-Baury B, Halna JM, Schmutz JL, Delvincourt C, Reuter G, Dalle S, Bernard P, Danzon A, Grange F. Durbec F, et al. Among authors: dalac s. Arch Dermatol. 2010 Mar;146(3):240-6. doi: 10.1001/archdermatol.2010.10. Arch Dermatol. 2010. PMID: 20231493
Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients.
Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N, Vignon-Pennamen MD, Costes-Martineau V, Lamant L, Dalac S, Delattre C, Déchelotte P, Courville P, Carlotti A, De Muret A, Fraitag S, Levy A, Mitchell A, Petrella T. Julia F, et al. Among authors: dalac s. Am J Surg Pathol. 2014 May;38(5):673-80. doi: 10.1097/PAS.0000000000000156. Am J Surg Pathol. 2014. PMID: 24441662
Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France.
Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, Maubec E, D'Incan M, Ram-Wolff C, Dalac S, Templier I, Esteve E, Quereux G, Machet L, Leduc M, Dereure O, Laroche L, Saiag P, Vergier B, Beylot-Barry M. Grange F, et al. Among authors: dalac s. JAMA Dermatol. 2014 May;150(5):535-41. doi: 10.1001/jamadermatol.2013.7452. JAMA Dermatol. 2014. PMID: 24647650
Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma.
Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Dompmartin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, Mateus C. Jouary T, et al. Among authors: dalac s. Acta Derm Venereol. 2015 Sep;95(7):835-40. doi: 10.2340/00015555-2099. Acta Derm Venereol. 2015. PMID: 25784178 Free article.
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C; GCC (French Group of Skin Cancer). Delyon J, et al. Among authors: dalac s. J Invest Dermatol. 2018 Jan;138(1):58-67. doi: 10.1016/j.jid.2017.07.839. Epub 2017 Aug 24. J Invest Dermatol. 2018. PMID: 28843487 Free article. Clinical Trial.
151 results